Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

FOCIS 2014: Spotlight on Translational Immunology
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Remyelination in experimental models of toxin-induced demyelination.
Episode 22 with Dr. Paul Matthews discussing the Optimize project in the UK
2015 Annual Meeting of the Consortium of the Multiple Sclerosis Centers
ACTRIMS-ECTRIMS 2014 -- Day 1, afternoon
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Transfer of interferon β-1a into human breastmilk.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
EAE: an immunologist's magic eye.
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.
Cigarette smoking and autoimmune disease: what can we learn from epidemiology?
ECTRIMS 2015
Episode 56 with Dr. Gavin Giovannoni, on early phase 3 results of ocrelizumab, the first experimental drug to show some benefit in a progressive form of multiple sclerosis in a major trial
Scientific discussion for the approval of Masivet
MS Research Roundup: January 29, 2014
Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
MS Research Roundup: January 31, 2014
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.

Pages